

Disclosure of related party transactions for the half year ended September 30, 2024

(Rs. in lakhs)

S. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty			Value of the related party transaction as approved by the audit committee/ Board	Value of transaction during the reporting period HY September 2024			Additional disclosure of related party transactions - applicable only in case the related party								
		Name	Name	Relationship of the counterparty with the listed entity or its subsidiary			Type of related party transaction	Opening Balance	Closing balance	In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
										Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/)	Interest Rate (%)	Tenure	Secured / unsecured	Purpose for which the funds will be utilised by the ultimate recipient of
1	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Sale of goods	5,650.00	2,526.09	2,556.50	2,812.94									
2	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Marketing Service Fees paid	2,000.00	942.78	-	-365.57									
3	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Sale of goods	1,300.00	106.34	-	106.53									
4	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Compensation Cost- ESOP recovery	75.00	33.95	89.44	123.80									
5	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Compensation Cost- ESOP recovery	75.00	37.35	183.29	221.19									
6	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Marketing support service	700.00	321.53	-43.09	-40.27									
7	J. B. Chemicals & Pharmaceuticals Limited	Biotech Laboratories (Pty.) limited	Subsidiary	Sale of goods	9,500.00	4,015.70	819.50	1,426.32									
8	J. B. Chemicals & Pharmaceuticals Limited	Biotech Laboratories (Pty.) limited	Subsidiary	Technical service fee received	400.00	143.64	12.17	88.30									
9	J. B. Chemicals & Pharmaceuticals Limited	Mr. Nikhil Chopra	KMP	*Remuneration (including retiral benefits)	803.00	401.50	-	-									
10	J. B. Chemicals & Pharmaceuticals Limited	Mr. Narayan Saraf	KMP	*Remuneration (including retiral benefits)	315.00	133.74	-	-									
11	J. B. Chemicals & Pharmaceuticals Limited	Mr. Sandeep Phadnis	KMP	*Remuneration (including retiral benefits)	79.75	39.16	-	-									
12	Unique Pharmaceutical Laboratories FZE	Mr. Sandeep Nasa	KMP	*Remuneration (including retiral benefits)	550.00	227.59	-	-									
13	Biotech Laboratories (Pty.) Limited	Mr. Stewart Barker	CEO of Subsidiary	*Remuneration (including retiral benefits)	430.00	197.39	-	-									
14	Unique Pharmaceutical Laboratories FZE	Mr. Stewart Barker	Employee of subsidiary	*Remuneration (including retiral benefits)	4.05	2.46	-	-									
15	Biotech Laboratories (Pty.) Limited	Mr. Shadrack Mapetla	Chairman of Board of subsidiary	Sitting fees	5.28	1.37	-	-									
16	J. B. Chemicals & Pharmaceuticals Limited	ipharma (Pty.) Ltd., South Africa	Spouse of subsidiary's CEO is director and minority shareholder	Sale of goods	1,500.00	205.32	451.58	155.29									
17	Biotech Laboratories (Pty.) Limited	ipharma (Pty.) Ltd., South Africa	Spouse of subsidiary's CEO is director and minority shareholder	Purchase of goods	3,300.00	634.52	-186.60	-55.00									
18	J. B. Chemicals & Pharmaceuticals Limited	Tau Investment Holdings Pte. Ltd.	Holding Company	Dividend paid	5,633.86	5,633.86	-	-									
Total																	

Note:

*Remuneration (excluding ESOP cost).
Negative figures represent the outstanding payables.